microsynth ag

Microsynth (founded in 1989) is a leading company in Europe in the field of DNA/RNA syntheses & analyses. The main activities are divided into the following three business areas: 1. DNA/RNA SYNTHESES ›DNA/RNA oligonucleotides (unmodified, modified, various purity grades) for various R&D applications › Primers and probes (e.g. OEM kit production) for molecular diagnostics › antisense oligonucleotides as well as siRNAs for drug discovery 2. DNA/RNA ANALYSES AND SEQUENCING › DNA Sanger sequencing of all types (incl. GMP sequencing) › Next generation sequencing (de novo & re-sequencing at the genome level, RNA-Seq, metagenome and amplicon sequencing, bioinformatics, etc.) › PCR, qPCR and digital PCR › Genotyping (fragment length analysis, cell line characterization, STR marker development, GBS) › DNA/RNA isolations (all sources, including high-throughput format) 3. CONTRACT RESEARCH/OUTSOURCING › Assay establishment & validation (e.g. IVD, animal and food diagnostics) › Biological testing (e.g. lot release mRNA vaccines) › Gene editing/gene therapy (e.g. CRISPR on/off target GxP analyses, rAAV characterization) Microsynth employs >100 people and has branch offices in Germany (Microsynth Seqlab), France (Microsynth France), Austria (Microsynth Austria) and Switzerland (ecogenics). Microsynth is ISO 9001:2015-, ISO 13485:2016- (oligonucleotide synthesis, kit production), ISO/IEC 17025:2017 (STS 0429) - (NGS, Sanger sequencing, fragment length analysis) and GMP certified (Sanger sequencing). We’re truly proud to be a pillar of scientific progress in pharma, biotech, and medicine. Since being founded in 1989, we’ve been incredibly passionate about the synthesis and analysis of nucleic acids - whether it is for basic research, diagnostic, or therapeutic applications. We act quickly and we’re easy to do business with, and we always show respect for the environment in everything we do.

ADC Therapeutics

ADC Therapeutics is a commercial-stage global pioneer in the field of antibody drug conjugates (ADCs). Our goal is to be a leading ADC company that transforms the lives of those impacted by cancer. To achieve this, we are focused on unlocking the potential value of our robust ADC portfolio across two pillars of growth: hematology and solid tumors. We are a pioneer in the ADC field with specialized end-to-end capabilities unique to ADCs including a validated technology platform, a growing next-generation research & development toolbox and a proven track record that includes an approved and marketed product. We aim to expand our portfolio and accelerate the development of our pipeline through targeted investments and in collaboration with strategic partners. In this way, we plan to pursue multiple targets in parallel, enabling us to prioritize and ensure disciplined capital allocation strategy while advancing the most promising candidates in both hematology and solid tumors. Our CD19-directed ADC ZYNLONTA® (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. Founded in 2011, ADC Therapeutics is based in Lausanne, Switzerland, with operations in London and New Jersey. Our highly skilled global team is committed to confronting cancer with the full potential of our science and transforming the treatment paradigm for patients with cancer. For more information, please visit https://www.adctherapeutics.com/.

Karius

Karius sees a world where infectious disease is no longer a major threat to human health. The Karius Test uses genomics and AI to map a patient’s microbial landscape from a single blood sample to enable clinicians to make rapid treatment decisions.

MicroGenDX

MicroGenDX provides qPCR+NGS sequencing for the detection of infectious diseases. The American Medical Association (AMA) and Medicare have issued a billing code to MicroGenDX to provide this testing service, recognizing this technology as medically necessary. MicroGenDX is trusted by over 39,000 physicians worldwide and has helped over 900,000 patients with diagnostic testing for their chronic and life-threatening infections. MicroGenDX is a College of American Pathologists (CAP) accredited and Clinical Laboratory Improvements Amendments (CLIA) licensed clinical laboratory. Tens of thousands of patients with chronic and often life-threatening infections have benefited from MicroGenDX’s work. MicroGenDX's NGS technology offers several advantages over traditional culture-based methods for identifying microorganisms. It can detect a wider range of microorganisms, including those that are difficult to culture or grow in a laboratory. It also provides more accurate and comprehensive results, as it can detect multiple microorganisms in a single sample and identify them at the species or strain level. Additionally, NGS technology is faster than traditional methods, allowing for quicker diagnosis and treatment decisions.  MicroGenDX's testing services are used in a variety of settings, including hospitals, long-term care facilities, dental offices, and veterinary clinics. Their technology has been applied to a wide range of clinical conditions, including chronic wounds, orthopedic infections, respiratory infections, and urinary tract infections, among others.

lucence

Lucence is a precision oncology company committed to bringing clarity to cancer care. Lucence makes ultrasensitive non-invasive liquid biopsy tests to provide doctors and their patients life-changing information to enable earlier detection and effective treatment. Headquartered in Palo Alto and Singapore, Lucence supplies personalized cancer care services through twin CLIA-licensed laboratories in the United States and Singapore. For more information, visit www.lucence.com.